Overview
Activ Surgical develops digital surgery tools that help surgeons see and understand real-time data during operations. Its core product, ActivSight Intelligent Light, provides intraoperative visualization and data to guide decisions, integrating with standard operating room workflows. The company differentiates itself through a focus on real-time surgical intelligence and automation, highlighted by a history of autonomous suturing milestones and its B2B model selling systems and services to hospitals and surgical centers. Its goal is to make advanced surgical visualization and decision support readily available to improve surgical performance and patient outcomes across many procedures.
Work here?Claim your company
Simplify's take
What believers are saying
- Activ raised $45 million in 2026 from Cota, Magnetar, and NVIDIA-backed investors.
- The company reports 122% year-over-year case growth and commercial activity across 15 countries.
- Partner pages and FDA listings show 2026 commercialization momentum for ActivSight and ActivConnect.
What critics are saying
- Stryker's $400 million CMR Surgical push intensifies platform competition, squeezing Activ's distribution window.
- Activ's regulatory moat is thin; K203550 hardware listings can be displaced by faster-cleared competitors.
- If hospitals prefer incumbent robot ecosystems, Activ becomes a niche accessory vendor before 2028.
What makes Activ unique
- ActivSight remains FDA-cleared and CE-marked, spanning robotic, laparoscopic, microscopy, and open surgery.
- Activ claims 2,000-plus cases and continuous dye-free perfusion visualization, unlike single-shot ICG checks.
- ActivInsights launched in 2026, extending hardware-agnostic visualization toward AI-guided intraoperative decision support.
Help us improve and share your feedback! Did you find this helpful?